COVID-19 has shown how Big Pharma is broken
Charlotte Kilpatrick of Salon writes about the motives that pharmaceutical companies have to invest in R&D for underfunded global health threats, such as coronaviruses.
Date
20 February 2021
In this piece, the author writes about the ways that pharmaceutical companies choose where to invest their money. Referencing a key finding from the 2021 Access to Medicine Index, Kilpatrick writes that in 2020, only 6 of 16 threatening pathogens identified by the WHO in 2016 were being researched by pharma companies.Â
Read the full article here.Â